<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04618146</url>
  </required_header>
  <id_info>
    <org_study_id>680-9\2020</org_study_id>
    <nct_id>NCT04618146</nct_id>
  </id_info>
  <brief_title>Enhanced Recovery After Cesarean Section With Low Dose Intrathecal Morphine.</brief_title>
  <official_title>Enhanced Recovery After Cesarean Section With Low Dose Intrathecal Morphine. A Prospective Randomized Controlled Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Minia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Minia University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to see the effect of low dose intrathecal morphine on promting&#xD;
      enhanced recovery after cesarean delivery with early ambulation and reduction of hospital&#xD;
      stay.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Parturients showing for elective cesarean section will be randomized into 3 groups by a&#xD;
      computer generated randomization list. Each randomization slip will be put in a sealed&#xD;
      envelope until patient enrollment. Patients will be divided into Group C: control group,&#xD;
      given intrathecal bupivacaine 12.5 mg. Group M25: intrathecal bupivacaine 12.5mg + morphine&#xD;
      25 microgram. Group M50: intrathecal bupivacaine 12.5mg + morphine 50 microgram.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 10, 2020</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain postoperative</measure>
    <time_frame>2 hours postoperatively</time_frame>
    <description>postoperative pain using Numerical pain score 0 no pain - 10 severe intolerable pain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain postoperative</measure>
    <time_frame>4 hours postoperatively</time_frame>
    <description>postoperative pain using Numerical pain score 0 no pain - 10 severe intolerable pain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain postoperative</measure>
    <time_frame>24 hours postoperatively</time_frame>
    <description>postoperative pain using Numerical pain score 0 no pain - 10 severe intolerable pain</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>vomiting</measure>
    <time_frame>2 hours postoperative</time_frame>
    <description>four-point rating score (1: no nausea or vomiting, 2: queasy, 3: severe nausea, 4: vomiting).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>vomiting</measure>
    <time_frame>4 hours postoperative</time_frame>
    <description>four-point rating score (1: no nausea or vomiting, 2: queasy, 3: severe nausea, 4: vomiting).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>vomiting</measure>
    <time_frame>24 hours postoperative</time_frame>
    <description>four-point rating score (1: no nausea or vomiting, 2: queasy, 3: severe nausea, 4: vomiting).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>itching</measure>
    <time_frame>2 hours postoperative</time_frame>
    <description>four-point rating score (1: no itching, 2: mild,face, no traetment needed 3: severe itching, allover the body).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>itching</measure>
    <time_frame>4 hours postoperative</time_frame>
    <description>four-point rating score (1: no itching, 2: mild,face, no traetment needed 3: severe itching, allover the body).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>itching</measure>
    <time_frame>24 hours postoperative</time_frame>
    <description>four-point rating score (1: no itching, 2: mild,face, no traetment needed 3: severe itching, allover the body).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>respiratory depression</measure>
    <time_frame>4 hours postoperative</time_frame>
    <description>respiratory rate less than 8 breaths \ minute</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Pain, Postoperative</condition>
  <condition>Pruritus</condition>
  <condition>Nausea, Postoperative</condition>
  <condition>Vomiting, Postoperative</condition>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>given intrathecal bupivacaine 12.5 mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group M25</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>given intrathecal bupivacaine 12.5mg + morphine 25 microgram.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group M50</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>given intrathecal bupivacaine 12.5mg + morphine 50 microgram.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine Sulfate</intervention_name>
    <description>intrathecal low dose morphine for early return to normal activity without opioid related complications.</description>
    <arm_group_label>Group M25</arm_group_label>
    <arm_group_label>Group M50</arm_group_label>
    <other_name>morphine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine Hydrochloride</intervention_name>
    <description>intrathecal bupivacaine 0.5%</description>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_label>Group M25</arm_group_label>
    <arm_group_label>Group M50</arm_group_label>
    <other_name>marcaine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Females scheduled for cesarean section&#xD;
&#xD;
          -  Age: 16-45 yrs.&#xD;
&#xD;
          -  Gestation age &gt;38 weeks.&#xD;
&#xD;
          -  ASA I,II&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Refusal to participate.&#xD;
&#xD;
          -  Significant cardiac, hepatic or renal dysfunction.&#xD;
&#xD;
          -  History of chronic itching problem, or hyperemesis during pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>females presenting for cesarean section</gender_description>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sohair A Megalla, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Anesthesia and ICU department, Faculty of Medicine, Minia University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sohair A Megalla, MD</last_name>
    <phone>+20 120 003 6447</phone>
    <email>Sohair.Adeeb@minia.edu.eg</email>
  </overall_contact>
  <location>
    <facility>
      <name>Minia university</name>
      <address>
        <city>Minya</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sohair A Megalla, MD</last_name>
      <phone>01200036447</phone>
      <email>Sohair.Adeeb@minia.edu.eg</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>November 1, 2020</study_first_submitted>
  <study_first_submitted_qc>November 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2020</study_first_posted>
  <last_update_submitted>February 26, 2021</last_update_submitted>
  <last_update_submitted_qc>February 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Minia University</investigator_affiliation>
    <investigator_full_name>Sohair Adeeb</investigator_full_name>
    <investigator_title>Principle investigator</investigator_title>
  </responsible_party>
  <keyword>pain</keyword>
  <keyword>morphine</keyword>
  <keyword>cesarean section</keyword>
  <keyword>enhanced recovery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pruritus</mesh_term>
    <mesh_term>Vomiting</mesh_term>
    <mesh_term>Pain, Postoperative</mesh_term>
    <mesh_term>Postoperative Nausea and Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

